Evidence map›Paper›PMID 35665873›Full record

ReviewInflammopharmacology2022

Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action.

Ana Muñoz-Jurado, Begoña M Escribano, Javier Caballero-Villarraso, Alberto Galván, Eduardo Agüera, Abel Santamaría, Isaac Túnez

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Inflammopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 3 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. [Melatonin alleviates cardiomyocyte necroptosis in diabetic mice by inhibiting the STING signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  7. Review
  8. Observational
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Melatonin amelioratesGenes & diseases · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Ana Muñoz-Jurado *Department of Cell Biology, Physiology and Immunology, Faculty of Veterinary Medicine, Campus of Rabanales, University of Cordoba, 14071, Cordoba, Spain. b22mujua@uco.es.ORCID http://orcid.org/0000-0002-7908-861X
Begoña M Escribano *Department of Cell Biology, Physiology and Immunology, Faculty of Veterinary Medicine, Campus of Rabanales, University of Cordoba, 14071, Cordoba, Spain.
Javier Caballero-VillarrasoMaimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain.
Alberto GalvánMaimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain.
Eduardo AgüeraMaimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain.
Abel SantamaríaLaboratory of Exciting Amino Acids, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
Isaac TúnezMaimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain. itunez@uco.es.ORCID http://orcid.org/0000-0002-4493-7087
Instituto Maimónides de Investigación Biomédica de Córdoba · ESInstituto Nacional de Neurología y Neurocirugía · MXUniversity of Córdoba · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMelatonin is an indole hormone secreted primarily by the pineal gland that showing anti-oxidant, anti-inflammatory and anti-apoptotic capacity. It can play an important role in the pathophysiological mechanisms of various diseases. In this regard, different studies have shown that there is a relationship between Melatonin and Multiple Sclerosis (MS). MS is a chronic immune-mediated disease of the Central Nervous System.

aimThe objective of this review was to evaluate the mechanisms of action of melatonin on oxidative stress, inflammation and intestinal dysbiosis caused by MS, as well as its interaction with different hormones and factors that can influence the pathophysiology of the disease.

resultsMelatonin causes a significant increase in the levels of catalase, superoxide dismutase, glutathione peroxidase, glutathione and can counteract and inhibit the effects of the NLRP3 inflammasome, which would also be beneficial during SARS-CoV-2 infection. In addition, melatonin increases antimicrobial peptides, especially Reg3β, which could be useful in controlling the microbiota.

conclusionMelatonin could exert a beneficial effect in people suffering from MS, running as a promising candidate for the treatment of this disease. However, more research in human is needed to help understand the possible interaction between melatonin and certain sex hormones, such as estrogens, to know the potential therapeutic efficacy in both men and women.

Indexed as

COVID-19MelatoninMultiple SclerosisAdjuvants, ImmunologicAnti-Inflammatory AgentsAntioxidantsCatalaseEstrogensFemaleGlutathioneGlutathione PeroxidaseHumansInflammasomesMaleNLR Family, Pyrin Domain-Containing 3 ProteinOxidative StressAdjuvants, ImmunologicAnti-Inflammatory AgentsAntioxidantsCatalaseEstrogensGlutathioneGlutathione PeroxidaseInflammasomesMelatoninNLR Family, Pyrin Domain-Containing 3 ProteinSuperoxide DismutaseInflammationIntestinal dysbiosisMelatoninMultiple sclerosisOxidative stress

Identifiers

PMID35665873
PMCPMC9167428
OpenAlexW4281855432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.